Business Description
AbCellera Biologics Inc
NAICS : 541720
SIC : 3741
ISIN : CA00288U1066
Share Class Description:
ABCL: Ordinary SharesTotal Employee Number:
562Compare
Compare
Traded in other countries / regions
ABCL.USA8QQ.Germany Index Membership
Russell 3000Russell 2000 IPO Date
2020-12-11Description
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.6 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.84 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.77 | |||||
Beneish M-Score | -0.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -45.3 | |||||
3-Year Book Growth Rate | -9.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -18.54 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 90.36 | |||||
9-Day RSI | 79.85 | |||||
14-Day RSI | 73.42 | |||||
3-1 Month Momentum % | 57.91 | |||||
6-1 Month Momentum % | 47.77 | |||||
12-1 Month Momentum % | 41.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.05 | |||||
Quick Ratio | 13.89 | |||||
Cash Ratio | 10.67 | |||||
Days Sales Outstanding | 206.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | -3.23 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -249.84 | |||||
Net Margin % | -181.75 | |||||
EBITDA Margin % | -210.86 | |||||
FCF Margin % | -238.91 | |||||
OCF Margin % | -193.5 | |||||
ROE % | -14.69 | |||||
ROA % | -10.64 | |||||
ROIC % | -21.01 | |||||
3-Year ROIIC % | -146.2 | |||||
ROC (Joel Greenblatt) % | -45.58 | |||||
ROCE % | -15.36 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 27.95 | |||||
PB Ratio | 2.39 | |||||
Price-to-Tangible-Book | 2.63 | |||||
EV-to-EBIT | -9.55 | |||||
EV-to-Forward-EBIT | 11.91 | |||||
EV-to-EBITDA | -11.31 | |||||
EV-to-Forward-EBITDA | 10.56 | |||||
EV-to-Revenue | 23.85 | |||||
EV-to-Forward-Revenue | 6.53 | |||||
EV-to-FCF | -9.98 | |||||
Price-to-GF-Value | 1.31 | |||||
Price-to-Projected-FCF | 3.95 | |||||
| Price-to-Net-Current-Asset-Value | 7.61 | |||||
| Price-to-Net-Cash | 16.4 | |||||
Earnings Yield (Greenblatt) % | -10.47 | |||||
FCF Yield % | -8.4 |
AbCellera Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AbCellera Biologics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 133 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 132 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 17:00 | In 42 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 41 days | ||
| General meeting for 2026 | 2026-06-11 09:00 | 5.09 (-2.12%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 11:40 | 5.72 (-4.75%) | ||
| Bank of America Health Care Conference | 2026-05-13 17:00 | 4.95 (+3.99%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 17:00 | 5.24 (+6.94%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 5.24 (+6.94%) | ||
| KeyBanc Capital Markets Healthcare Forum | 2026-03-17 | 3.56 (+0.56%) |
Show
Entries
Guru Commentaries on NAS:ABCL
No articles.
Press Release
Articles on AbCellera Biologics Inc
No articles.
Headlines
See More- 1
Jun 17, 2026
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Benzinga • 11:54am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers